文献速递妇产影像泌尿生殖US

有乳腺癌病史患者附件肿块评估中主观评估与IOTA ADNEX模型的应用

Subjective assessment and IOTA ADNEX model in evaluation of adnexal masses in patients with history of breast cancer.
PubMed 文献 · Ultrasound Obstet Gynecol · 2023-01-01

回顾性单中心研究纳入2013–2020年间因附件肿块手术的202例乳腺癌病史患者,以最终组织学为参考标准,比较主观评估与ADNEX模型鉴别良恶性及原发与转移性附件肿瘤的表现;两者鉴别良恶性准确性相似,鉴别转移与原发肿瘤准确性好但敏感度低。

要点

  • 乳腺癌病史患者附件肿块中转移瘤占16.3%(33/202),阅片需警惕转移可能。
  • 主观评估鉴别良恶性敏感度93.6%、特异度84.9%、准确率89.6%。
  • ADNEX模型鉴别良恶性敏感度98.2%、特异度78.5%、准确率89.1%。

核心结论

  • 在该乳腺癌病史患者系列中,主观评估与ADNEX模型鉴别附件肿块良恶性的表现相对相似。
  • 两者鉴别转移性与原发肿瘤的准确率和特异度均好,但敏感度低。

研究设计与样本

  • 回顾性单中心研究,纳入2013–2020年间因附件肿块接受手术且有乳腺癌病史的患者202例。
  • 所有患者均接受经阴道或经直肠超声标准化检查,超声报告存档并调取分析。
  • 分析调取报告中原始超声检查者提示的具体诊断,ADNEX模型风险为前瞻性计算并以最高相对风险将肿块归入五类之一。
  • 以最终组织学为参考标准,评估主观评估与ADNEX模型鉴别良恶性及原发与转移性附件肿瘤的表现。

关键影像表现/征象

  • 组织学显示良性肿块93/202(46.0%),原发恶性肿瘤76/202(37.6%,含4例交界性和72例浸润性肿瘤),转移瘤33/202(16.3%)。
  • 原始超声检查者正确分类良性附件肿块79/93(84.9%)、原发附件恶性肿瘤72/76(94.7%)、转移瘤30/33(90.9%)。

诊断标准与关键数值

  • 主观超声评估鉴别良恶性附件肿块的敏感度93.6%、特异度84.9%、准确率89.6%。
  • ADNEX模型鉴别良恶性附件肿块的敏感度98.2%、特异度78.5%、准确率89.1%。
  • 主观评估鉴别转移性与原发肿瘤(含良性、交界性和浸润性肿瘤)的敏感度51.5%、特异度88.8%、准确率82.7%。
  • ADNEX模型鉴别转移性与原发肿瘤的敏感度63.6%、特异度84.6%、准确率81.2%。

临床应用与阅片要点

  • 对有乳腺癌病史的附件肿块患者,主观评估与ADNEX模型均可用于良恶性鉴别,两者准确率相似。
  • 鉴别转移性与原发肿瘤时,主观评估与ADNEX模型准确率和特异度好但敏感度低,阅片报告需注意这一局限。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the performance of subjective assessment and the Assessment of Different NEoplasias in the adneXa (ADNEX) model in discriminating between benign and malignant adnexal tumors and between metastatic and primary adnexal tumors in patients with a personal history of breast cancer.

METHODS: This was a retrospective single-center study including patients with a history of breast cancer who underwent surgery for an adnexal mass between 2013 and 2020. All patients had been examined with transvaginal or transrectal ultrasound using a standardized examination technique and all ultrasound reports had been stored and were retrieved for the purposes of this study. The specific diagnosis suggested by the original ultrasound examiner in the retrieved report was analyzed. For each mass, the ADNEX model risks were calculated prospectively and the highest relative risk was used to categorize each into one of five categories (benign, borderline, primary Stage I, primary Stages II-IV or metastatic ovarian cancer) for analysis of the ADNEX model in predicting the specific tumor type. The performance of subjective assessment and the ADNEX model in discriminating between benign and malignant adnexal tumors and between primary and metastatic adnexal tumors was evaluated, using final histology as the reference standard.

RESULTS: Included in the study were 202 women with a history of breast cancer who underwent surgery for an adnexal mass. At histology, 93/202 (46.0%) masses were benign, 76/202 (37.6%) were primary malignancies (four borderline and 72 invasive tumors) and 33/202 (16.3%) were metastases. The original ultrasound examiner classified correctly 79/93 (84.9%) benign adnexal masses, 72/76 (94.7%) primary adnexal malignancies and 30/33 (90.9%) metastatic tumors. Subjective ultrasound evaluation had a sensitivity of 93.6%, specificity of 84.9% and accuracy of 89.6%, while the ADNEX model had higher sensitivity (98.2%) but lower specificity (78.5%), with similar accuracy (89.1%), in discriminating between benign and malignant ovarian masses. Subjective evaluation had a sensitivity of 51.5%, specificity of 88.8% and accuracy of 82.7% in distinguishing metastatic and primary tumors (including benign, borderline and invasive tumors), and the ADNEX model had a sensitivity of 63.6%, specificity of 84.6% and similar accuracy (81.2%).

CONCLUSIONS: The performance of subjective assessment and the ADNEX model in discriminating between benign and malignant adnexal masses in this series of patients with history of breast cancer was relatively similar. Both subjective assessment and the ADNEX model demonstrated good accuracy and specificity in discriminating between metastatic and primary tumors, but the sensitivity was low. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Pozzati F, Sassu CM, Marini G, et al. Subjective assessment and IOTA ADNEX model in evaluation of adnexal masses in patients with history of breast cancer. Ultrasound Obstet Gynecol. 2023. PMID: 37204769. doi:10.1002/uog.26253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。